bismuth subcitrate 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4355	57644-54-9

Description:

Molecule

Description

Synonyms:

bismuth subcitrate
bismuth tripotassium dicitrate
bismuth subcitrate potassium

contains tripotassium di-citratobismuthate used in gastric & duodenal ulcer therapy; do not confuse with colloidal bismuth subnitrate

Molecular weight: 704.47
Formula: C12H10BiK3O14
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA: 140.62
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.48	g	O

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
Sept. 28, 2006	FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Drug eruption	67.92	56.65	16	146	43919	79700307

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A02BD08	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Combinations for eradication of Helicobacter pylori
ATC	A02BX05	ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD) Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)
MeSH PA	D000863	Antacids
MeSH PA	D000890	Anti-Infective Agents
MeSH PA	D000897	Anti-Ulcer Agents
MeSH PA	D005765	Gastrointestinal Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Duodenal Ulcer due to H. Pylori	indication
Alcoholism	contraindication	7200002
Lowered convulsive threshold	contraindication	19260006
Alcohol intoxication	contraindication	25702006
Hepatic failure	contraindication	59927004
Blood coagulation disorder	contraindication	64779008	DOID:1247
Diabetes mellitus	contraindication	73211009	DOID:9351
Disorder of brain	contraindication	81308009	DOID:936
Gout	contraindication	90560007	DOID:13189
Kidney disease	contraindication	90708001	DOID:557
Seizure disorder	contraindication	128613002
Non-infective meningitis	contraindication	230155003
Disease of liver	contraindication	235856003	DOID:409
Pregnancy, function	contraindication	289908002
Peripheral nerve disease	contraindication	302226006
Neutropenic disorder	contraindication	303011007	DOID:1227
Pseudomembranous enterocolitis	contraindication	397683000
Breastfeeding (mother)	contraindication	413712001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
140MG;125MG;125MG	BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE AND TETRACYCLINE HYDROCHLORIDE	RICONPHARMA LLC	A217511	July 3, 2023	RX	CAPSULE	ORAL	Dec. 29, 2023	COMPETITIVE GENERIC THERAPY

Bioactivity Summary:

None

External reference:

ID	Source
4026166	VUID
N0000179322	NUI
D09739	KEGG_DRUG
4026166	VANDF
C0106556	UMLSCUI
CHEMBL1201186	ChEMBL_ID
CHEMBL1744033	ChEMBL_ID
C002791	MESH_SUPPLEMENTAL_RECORD_UI
HS813P8QPX	UNII
10101269	PUBCHEM_CID
DB09275	DRUGBANK_ID
1294617	RXNORM
23879	MMSL
d04952	MMSL
003773	NDDF
396007005	SNOMEDCT_US
420020009	SNOMEDCT_US
735064002	SNOMEDCT_US
737682001	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Bismuth Subcitrate Potassium, Metronidazole and Tetracycline Hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	3	49884-151	CAPSULE	140 mg	ORAL	ANDA	27 sections
Bismuth subcitrate potassium, Metronidazole, Tetracycline hydrochloride	HUMAN PRESCRIPTION DRUG LABEL	3	50742-283	CAPSULE	140 mg	ORAL	ANDA	20 sections
Pylera	HUMAN PRESCRIPTION DRUG LABEL	3	54868-6151	CAPSULE	140 mg	ORAL	NDA	27 sections
Pylera	HUMAN PRESCRIPTION DRUG LABEL	3	58914-601	CAPSULE	140 mg	ORAL	NDA	32 sections
Pylera	HUMAN PRESCRIPTION DRUG LABEL	3	58914-601	CAPSULE	140 mg	ORAL	NDA	32 sections
BISMUTH SUBCITRATE POTASSIUM, METRONIDAZOLE, AND TETRACYCLINE HYDROCHLORIDE	HUMAN PRESCRIPTION DRUG LABEL	3	61269-385	CAPSULE	140 mg	ORAL	NDA	32 sections